Aim. The cardiotoxicity of anticancer drugs is an emerging problem and only an identification of the early signs of cardiotoxicity by conventional echocardiography and not (tissue Doppler imaging, TDI), will limit and contain the long-term cardiotoxicity effects. The aim of this study was to identify, through conventional echocardiography and TDI, parameters to use as early "signs" of cardiotoxicity. Methods. A prospective study was performed using patients with breast cancer (72 women, median age 57+/-12) treated with anticancer drugs (adjuvant chemotherapy). All patients underwent a careful cardiological evaluation before starting treatment (T0) and during follow-up at 3 months (T1), 6 months (T2) and 1 year (T3). Electrocardiography a...
Background: Cardiomyopathy following anthracycline chemotherapy may have ominous clinical implicatio...
Abstract Background Cardiotoxic effects of anthracycline therapy are a major cause of morbidity for ...
Cardiologists and oncologists today face the daunting challenge of identifying patients at risk for ...
Aim. The cardiotoxicity of anticancer drugs is an emerging problem and only an identification of the...
Cardiotoxicity is a common complication of chemotherapy. The aim of this study was to assess the car...
Background Chemotherapy cardiotoxicity is an emerging problem and it is very important to prevent ca...
<p>Background: The cardiotoxic effects of many chemotherapeutics are well reported. These effects va...
Anthracyclines are established cardiotoxic agents; however, the exact extent and time course of such...
Abstract Cancer therapy has shown terrific progress leading to important reduction of morbidity and ...
Aim. Anthracycline (ANT) chemotherapy for breast cancer, while associated with high response rates, ...
The evaluation by cardiovascular imaging of chemotherapy patients became a central topic in the last...
The evaluation by cardiovascular imaging of chemotherapy patients became a central topic in the last...
Background: Because cancer patients survive longer, the impact of cardiotoxicity associated with the...
Several anticancer agents are associated with significant cardiotoxicity. The list of cardiotoxic ca...
Objective: Cardiac effects of chemotherapy are usually recognized after clinical symptom or sign occ...
Background: Cardiomyopathy following anthracycline chemotherapy may have ominous clinical implicatio...
Abstract Background Cardiotoxic effects of anthracycline therapy are a major cause of morbidity for ...
Cardiologists and oncologists today face the daunting challenge of identifying patients at risk for ...
Aim. The cardiotoxicity of anticancer drugs is an emerging problem and only an identification of the...
Cardiotoxicity is a common complication of chemotherapy. The aim of this study was to assess the car...
Background Chemotherapy cardiotoxicity is an emerging problem and it is very important to prevent ca...
<p>Background: The cardiotoxic effects of many chemotherapeutics are well reported. These effects va...
Anthracyclines are established cardiotoxic agents; however, the exact extent and time course of such...
Abstract Cancer therapy has shown terrific progress leading to important reduction of morbidity and ...
Aim. Anthracycline (ANT) chemotherapy for breast cancer, while associated with high response rates, ...
The evaluation by cardiovascular imaging of chemotherapy patients became a central topic in the last...
The evaluation by cardiovascular imaging of chemotherapy patients became a central topic in the last...
Background: Because cancer patients survive longer, the impact of cardiotoxicity associated with the...
Several anticancer agents are associated with significant cardiotoxicity. The list of cardiotoxic ca...
Objective: Cardiac effects of chemotherapy are usually recognized after clinical symptom or sign occ...
Background: Cardiomyopathy following anthracycline chemotherapy may have ominous clinical implicatio...
Abstract Background Cardiotoxic effects of anthracycline therapy are a major cause of morbidity for ...
Cardiologists and oncologists today face the daunting challenge of identifying patients at risk for ...